Navigation Links
Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
Date:11/12/2008

PARSIPPANY, N.J., Nov. 12 /PRNewswire/ -- Ferring Pharmaceuticals Inc. announces the promotion of William N. Garbarini, Jr. to Vice President of its new Orthopaedics and Urology Business Unit, recently formed by merging these clinical product areas. Garbarini was formerly Executive Director of Ferring's Orthopaedics Business Unit.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081112/NY45502 )

In his new role, Garbarini is responsible for Ferring's two marketed products in these areas, euflexxa(R) (1% sodium hyaluronate) for the pain caused by knee osteoarthritis, and PROSED(R) DS for the relief of discomfort of the lower urinary tract. He will also oversee the U.S. sales and marketing of Ferring's pipeline of urology products, including a GnRH antagonist for prostate cancer.

"Bill's exceptional talent, leadership and wealth of experience in pharmaceutical marketing have driven his rapid rise and recognition in the health care industry," said Wayne Anderson, President of Ferring. "After spearheading the growth of our infertility and orthopaedics businesses, he is extremely qualified to lead our new Orthopaedics and Urology unit."

During his tenure, Garbarini directed the launches of three key products in the Ferring portfolio. After joining Ferring in 2001 as a Product Director for its infertility franchise, he launched BRAVELLE(R), a highly purified, human-derived follicle-stimulating hormone (hFSH) for infertility treatment. Ferring quickly became a formidable player in the market and grew to become the leader in total infertility prescriptions.

Garbarini was soon promoted to the unit's Director of Marketing and oversaw the launch of MENOPUR(R) (menotropins for injection, USP), a purified human menopausal gonadotropin (hMG) for patients undergoing in vitro fertilization (IVF). The product grew Ferring's hMG segment and continued the Company's dominance in total infertility prescriptions.

In 2005, Garbarini became Senior Director of Marketing for Ferring's new Orthopaedic Business Unit, which further diversified Ferring's portfolio. He launched euflexxa(R) for the pain caused by knee osteoarthritis. Soon it became the fastest-growing product in Ferring's line. In 2006, he accepted further responsibility as the Executive Director of Sales and Marketing for the business unit.

Prior to joining Ferring, Garbarini was Director, Client Services for Caresoft, Inc. Previously, he served in various positions at Schering-Plough Corporation/Key Pharmaceuticals, Lowe McAdams Healthcare advertising agency, and Glaxo Wellcome, where he was honored as a top sales representative. Garbarini holds a B.S. degree in economics from the College of New Jersey and an M.B.A. degree in pharmaceutical management from Fairleigh Dickinson University, where he was granted membership in the Delta Mu Delta Honor Society.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring's line of products includes: EUFLEXXA(R) (hyaluronic acid) for pain from osteoarthritis in the knee; BRAVELLE(R) (urofollitropin for injection, purified); MENOPUR(R) (menotropins for injection, USP); REPRONEX(R) (menotropins for injection, USP); NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert for infertility. Ferring offers the Q?CAP(TM), the first needle-free reconstitution device, for use with its fertility treatments.

Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing's syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED(R) DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology, orthopaedics and infertility. For more information, call 888-337-7464 or visit http://www.FerringUSA.com.

CONTACT: Tara Fisher

Kovak-Likly Communications

203-762-8833 or tfisher@KLCpr.com


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest
2. Ferring Pharmaceuticals EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
3. Increase in Diagnostic Imaging Fueled by Self-Referring Doctors
4. Ferring Pharmaceuticals EUFLEXXA(R) to Serve as a Sponsor for the Babolat World Tennis Classic
5. Dr. Jan Linhart Now Offerring Unique Laser Teeth Whitening System
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general ... accepting new pediatric patients, with or without a referral. Dr. Cotey knows that ... orthodontic outcome and experience. When patients receive early treatment, they may achieve straight teeth ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... buildings (MOBs) and other outpatient facilities, and who are the most active developers? ... those questions, Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical ...
(Date:3/29/2017)... ... , ... Curio Wellness , a premium medical cannabis brand and trusted ... management team with prominent executives from both inside and outside the cannabis industry. ... Ted Dumbauld , who has more than twenty years of business leadership and investment ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar ... at 1:00 PM ET. A recording of the webinar will also be made available ... Home health and hospice companies are still popular targets for healthcare investors. This highly ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... March 30, 2017 Revenue Prospects by Product ... and COPD) and Geography Respiratory Inhalers - our new ... the Respiratory Inhalers market heading? If you are involved in this ... report shows you the potential revenues streams to 2027, assessing data, ... ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Neuromonitoring (IONM) Market Size & Forecast By Type (Insource IONM, ... 2025" report to their offering. ... The global Intraoperative Neuromonitoring ... 2025. The intraoperative neuromonitoring market is anticipated to witness significant ...
(Date:3/29/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The global energy-based aesthetic devices market to grow at ... The report, Global Energy-Based Aesthetic Devices Market 2017-2021, has been prepared ... The report covers the market landscape and its growth prospects over ...
Breaking Medicine Technology: